You are here

Production of a stable recombinant human butyrylcholinesterase

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: W911SR-21-C-5003
Agency Tracking Number: C2-0585
Amount: $558,524.52
Phase: Phase II
Program: SBIR
Solicitation Topic Code: CBD192-007
Solicitation Number: 19.2
Solicitation Year: 2019
Award Year: 2021
Award Start Date (Proposal Award Date): 2021-09-27
Award End Date (Contract End Date): 2023-09-30
Small Business Information
737 Concord Ave
Cambridge, MA 02138-1002
United States
DUNS: 080316838
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Piercen Oliver
 (617) 621-8500
Business Contact
 Philip Graf
Phone: (617) 621-8500
Research Institution

Human butyrylcholinesterase (BChE) is an effective bioscavenger of organophosphates and has potential for acting as a pre-exposure prophylactic or post-exposure treatment for organophosphate (OP) nerve agents, such as sarin. Ideally, a single dose of BChE could be administered and protect the warfighter for days or even weeks while in combat. To be effective in a military setting, especially as a prophylactic, BChE must have a very long serum half-life and must be non-immunogenic. It is now well-established that the plasma half-life of recombinant BChE is strongly affected by the extent of its oligomerization, glycosylation, and sialylation. During Phase II, we will scale up the expression and purification of a lead candidate recombinant BChE that meets or exceeds the blood serum half-life of wild-type human BChE. Efficacy of the recombinant BChE will be confirmed in vitro and in vivo, and a preliminary regulatory strategy will be established for evaluation by the FDA.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government